Long-term (52-week) efficacy and safety of dapagliflozin as an adjunct to insulin therapy in Japanese patients with type 1 diabetes: Subgroup analysis of the DEPICT-2 study.

Abstract

AIM:

To examine the long-term efficacy and safety of dapagliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor used to treat type 1 diabetes, in the Japanese subpopulation of the DEPICT-2 study.

MATERIALS AND METHODS:

Patients with type 1 diabetes were randomized to dapagliflozin 5 mg (n = 55), dapagliflozin 10 mg (n = 41) or placebo (n = 58) plus insulin for a 24-week, double-blind period followed by a 28-week, single-blind extension phase.

RESULTS:

From baseline to 24 weeks, dapagliflozin reduced HbA1c compared with placebo (mean change of -0.58% and -0.80% for 5 and 10 mg, respectively), and an HbA1c reduction was observed up to 52 weeks. Compared with placebo, dapagliflozin 5 and 10 mg increased the proportion of patients achieving HbA1c reductions of 0.5% or more without severe hypoglycaemia events and reduced glycaemic variability assessed via continuous glucose monitoring. Both dapagliflozin doses decreased body weight and total daily insulin dose at 24 weeks compared with placebo; these reductions were maintained up to 52 weeks. Diabetic ketoacidosis occurred in both dapagliflozin groups (one and two cases, respectively) but not with placebo.

CONCLUSIONS:

Efficacy and safety results from the Japanese subpopulation of the DEPICT-2 study were generally consistent with those from the overall population, indicating that long-term dapagliflozin adjunct to insulin therapy improves glycaemic control without an increased risk of hypoglycaemia but with a risk of diabetic ketoacidosis in Japanese patients with type 1 diabetes.

• Authors: Eiichi Araki, Chantal Mathieu, Toshihiko Shiraiwa, Hajime Maeda, Hiroki Ikeda, Fredrik Thoren, Niki Arya, Michiko Asano, Nayyar Iqbal
• Journal: Diabetes, obesity & metabolism (Diabetes Obes Metab) Vol. 23 Issue 7 Pg. 1496-1504 (07 2021) ISSN: 1463-1326 [Electronic] England
• PMID: 33620762 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: © 2021 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

Chemical References

• Benzhydryl Compounds
• Blood Glucose
• Glucosides
• Glycated Hemoglobin A
• Hypoglycemic Agents
• Insulin
• dapagliflozin

Topics

• Benzhydryl Compounds (adverse effects)
• Blood Glucose
• Blood Glucose Self-Monitoring
• Diabetes Mellitus, Type 1 (drug therapy)
• Double-Blind Method
• Drug Therapy, Combination
• Glucosides
• Glycated Hemoglobin (analysis)
• Humans
• Hypoglycemic Agents (adverse effects)
• Insulin (therapeutic use)
• Japan (epidemiology)
• Single-Blind Method
• Treatment Outcome